Pharmaceutical News

RSS

Common nerve pain drugs may set off prescribing cascades in older patients

Clinicians may fail to recognize common side effects of drugs like gabapentin - which are frequently prescribed for nerve pain - leading them to prescribe unnecessary medications that cause yet more side effects.

2 Dec 2025

WHO releases first guideline on the use of GLP-1 therapies for treating obesity

To address the growing global health challenge of obesity, which affects more than 1 billion people, the World Health Organization (WHO) has released its first guideline on the use of Glucagon-Like Peptide-1 (GLP-1) therapies for treating obesity as a chronic, relapsing disease.

2 Dec 2025

Breakthrough immunotherapy approved for treatment of adults with aggressive blood cancer

Adult patients with an aggressive form of leukemia will be able to receive a breakthrough immunotherapy, which was invented by UCL researchers, on the NHS within weeks following approval for use by the National Institute for Health and Care Excellence (NICE).

27 Nov 2025

UBC researchers reveal how statins trigger muscle damage

Statins have transformed heart health, saving millions of lives by lowering cholesterol and reducing the risk of heart attacks and strokes.

26 Nov 2025

Metformin fails to improve insulin resistance in type 1 diabetes

Metformin treatment in type 1 diabetes lowers insulin dosage but does not improve insulin resistance, highlighting its complex role in diabetes management.

26 Nov 2025

Most public speakers at FDA advisory committees support drug approval

U.S. Food and Drug Administration (FDA) advisory committees play a key role in evaluating the efficacy and safety of new drugs.

25 Nov 2025

New medication offers potential treatment for patients with deadliest form of blood cancer

Biomedical research that began at the University of Virginia School of Medicine has yielded a much-needed new treatment for patients with the deadliest form of blood cancer.

25 Nov 2025

GLP-1 discontinuation associated with more weight gain and pregnancy complications

In a study led by researchers at Mass General Brigham, pregnant individuals who stopped taking popular weight loss GLP-1 medications before or early in their pregnancy tended to gain more weight and have higher risks of diabetes and hypertensive disorders during pregnancy, and experienced preterm delivery more so than people who had never taken GLP-1 drugs.

24 Nov 2025

Study finds GLP-1 drugs improve strength and reverse aging biology in mice

Researchers showed that GLP-1 receptor agonism counteracts aging across multiple organs in mice, improving strength and reversing molecular aging signatures without meaningful effects on body weight. These benefits depended largely on hypothalamic GLP-1R signaling and closely mirrored the anti-aging patterns produced by rapamycin.

23 Nov 2025

Take-home methadone provides a lifesaving bridge to recovery after hospitalization

For patients recovering from opioid use disorder, particularly from drugs like fentanyl or heroin, the days immediately following a hospital stay are among the most dangerous.

22 Nov 2025

AMI urges stronger and more equitable global action plan on antimicrobial resistance

In World Antimicrobial Resistance Awareness Week (WAAW), Applied Microbiology International (AMI) has urged global policymakers to strengthen the revised Global Action Plan on Antimicrobial Resistance (GAP-AMR), calling for a more inclusive, clear and equitable approach to tackling one of the world's most urgent health challenges.

20 Nov 2025

Searches for “Ozempic face” surge as people look for filler-based solutions

Public interest in “Ozempic face” rose sharply from 2022 to 2025, mirrored by increased searches for nonsurgical facial filler procedures. Surgical terms showed neutral or negative associations, indicating consumers are primarily exploring filler-based solutions for GLP-1RA-related facial volume loss.

20 Nov 2025

Study compares GLP-1 drug benefits and finds substantial variation in clinical effects

GLP-1 receptor agonists improve glycaemic control and provide renal, metabolic, and selective cardiovascular benefits in people with type 2 diabetes, based on an umbrella review of 17 meta-analyses. However, these agents consistently increase gastrointestinal adverse effects and show important distinctions between class-level outcomes and individual drug effects, particularly for semaglutide.

20 Nov 2025

Study compares the kidney, cardiovascular and mortality risks of three different GLP-1 RAs

Public interest in drugs known as glucagon-like peptide-1 receptor agonists, also called GLP-1 RAs, has surged in recent years, with popular types like semaglutide (sold under brand names like Ozempic and Wegovy) becoming known for their weight-loss effects.

20 Nov 2025

Oral semaglutide delivers real-world drops in blood sugar and weight in diabetes trial

Oral semaglutide delivered meaningful reductions in HbA1c and body weight among GLP-1RA-naïve adults with type 2 diabetes in a Dutch real-world cohort. Lipid levels and blood pressure showed only small changes, reflecting modest cardiometabolic effects outside glucose and weight control.

18 Nov 2025

Tirzepatide reveals a brain signal that predicts returning food preoccupation

Researchers implanted electrodes in the human nucleus accumbens to track brain activity during severe food preoccupation in an individual taking tirzepatide. They found that a delta–theta biomarker disappeared during symptom-free periods and re-emerged weeks before relapse, suggesting a possible neural marker of vulnerability to dysregulated eating.

18 Nov 2025

Alzheimer’s drugs improve key cognitive skills in children with autism and low IQ

The review synthesizes evidence on whether Alzheimer’s disease medications can improve neurocognitive outcomes in children and adolescents with autism and low IQ. Across 12 studies, preliminary findings show promising gains in language, executive function, learning and memory, and general cognitive ability, particularly in younger children.

18 Nov 2025

Year-long adherence to buprenorphine sharply reduces overdose risk in young people

New research from Mass General Brigham finds that adolescents and young adults who stayed on the medication buprenorphine for at least a year had markedly lower risks of opioid overdose and hospitalization compared with peers who discontinued medication early or took it inconsistently.

18 Nov 2025

Yale study exposes unequal access to new medicines after clinical trials

A new study led by Yale's Jennifer Miller, PhD, found that medicines are not physically accessible in many of the countries where they are tested for FDA approval.

17 Nov 2025

Brain recordings reveal short-lived effects of tirzepatide on food cravings

A rare glimpse into the brain activity of a patient with obesity and loss of control eating on tirzepatide, marketed as Mounjaro and Zepbound, revealed that the medication suppresses signaling in the brain's "reward center" thought to be involved in food noise – but only temporarily.

17 Nov 2025

Pharmaceutical News

Common nerve pain drugs may set off prescribing cascades in older patients

WHO releases first guideline on the use of GLP-1 therapies for treating obesity

Breakthrough immunotherapy approved for treatment of adults with aggressive blood cancer

UBC researchers reveal how statins trigger muscle damage

Metformin fails to improve insulin resistance in type 1 diabetes

Most public speakers at FDA advisory committees support drug approval

New medication offers potential treatment for patients with deadliest form of blood cancer

GLP-1 discontinuation associated with more weight gain and pregnancy complications

Study finds GLP-1 drugs improve strength and reverse aging biology in mice

Take-home methadone provides a lifesaving bridge to recovery after hospitalization

AMI urges stronger and more equitable global action plan on antimicrobial resistance

Searches for “Ozempic face” surge as people look for filler-based solutions

Study compares GLP-1 drug benefits and finds substantial variation in clinical effects

Study compares the kidney, cardiovascular and mortality risks of three different GLP-1 RAs

Oral semaglutide delivers real-world drops in blood sugar and weight in diabetes trial

Tirzepatide reveals a brain signal that predicts returning food preoccupation

Alzheimer’s drugs improve key cognitive skills in children with autism and low IQ

Year-long adherence to buprenorphine sharply reduces overdose risk in young people

Yale study exposes unequal access to new medicines after clinical trials

Brain recordings reveal short-lived effects of tirzepatide on food cravings

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News